



## Press Release

April 12, 2018

Strides Shasun Limited  
Strides House, Bannerghatta Road,  
Bangalore – 560076.

---

# Strides Shasun receives USFDA Approval for Cyproheptadine Hydrochloride Tablets

## Product approval from Oral dosage facility at Bangalore

---

**Bangalore, April 12, 2018** Strides Shasun Limited today announced that its wholly owned subsidiary Strides Pharma Global Pte. Ltd. has received approval for **Cyproheptadine Hydrochloride Tablets USP, 4 mg** from the United States Food & Drug Administration (US FDA). Cyproheptadine Hydrochloride Tablets is a generic version of Periactin Tablets of Merck & Co. Inc.

According to IQVIA data, the US market for **Cyproheptadine Hydrochloride Tablets USP, 4 mg** is approximately USD 20 Million. The product will be manufactured at the company's Oral dosage facility at Bangalore and will be marketed by Strides Pharma Inc. in the US Market.

The company has 74 cumulative ANDA filings with USFDA of which 46 ANDAs have been approved as of date and 28 are pending approval.

### **About Cyproheptadine Hydrochloride Tablets**

Cyproheptadine Hydrochloride Tablets is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, sneezing, hives, and itching.

### **About Strides Shasun**

Strides Shasun, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets.

The Company has global manufacturing foot print with 7 manufacturing facilities spread across three continents including 5 US FDA approved facilities and 2 facilities for the emerging markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company's website at [www.stridesarco.com](http://www.stridesarco.com)

**For further information, please contact:**

<p><u>Strides</u></p> <p>Shashank Sinha, Managing Director +91 80 6784 0335</p> <p><u>Investors:</u></p> <p>Kannan. N: +91 98450 54745 Vikesh Kumar: +91 80 6784 0827 Sandeep Baid : +91 80 6784 0791</p> <p>Strides Shasun Limited CIN : L24230MH1990PLC057062 Regd. Office: 201, 'Devavrata', Sector – 17, Vashi, Navi Mumbai – 400 703 Email: <a href="mailto:investors@stridesshasun.com">investors@stridesshasun.com</a></p>	<p><u>PR Consultancy</u></p> <p>Fortuna PR K Srinivas Reddy: +91 9000527213 <a href="mailto:srinivas@fortunapr.com">srinivas@fortunapr.com</a></p> <p>K Priya: +91 9535425418 <a href="mailto:priya@fortunapr.com">priya@fortunapr.com</a></p>
---	--